TerminatedNot Applicable

Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants.

France87 participantsStarted 2016-01

Plain-language summary

This study evaluates the potential interest of a new multi-lumen infusion access device (Edelvaiss® Multiline NEO) in the prevention of catheter-related bacteremia when administering injectable drugs in premature infants. This device will be compared to the standard infusion set of each center.

Who can participate

Age range24 Weeks – 29 Weeks

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Infants with gestational ages between 24 and 29 weeks. * Infants carrying a single-lumen central venous catheter. * Obtaining the informed parental consent. Exclusion Criteria: * Infants carrying a multi-lumen central venous catheter. * Infants carrying a umbilical venous catheter. * Infants carrying two central venous catheters. * Refusal of informed parental consent.

What they're measuring

Measure of incidence density (ID) of catheter-related bacteremia (CRB)

Timeframe: Through an average of 30 days

Trial details

NCT IDNCT02633124

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-05

View on ClinicalTrials.gov More Bacteremia trials